399 related articles for article (PubMed ID: 28336182)
21. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
22. Coexistence of amyloidosis and light chain deposition disease in the heart.
Sobue Y; Takemura G; Kawamura S; Yano T; Kanamori H; Morimoto SI; Matsuo H
Cardiovasc Pathol; 2021; 51():107315. PubMed ID: 33264681
[TBL] [Abstract][Full Text] [Related]
23. Truncation of the constant domain drives amyloid formation by immunoglobulin light chains.
Lavatelli F; Natalello A; Marchese L; Ami D; Corazza A; Raimondi S; Mimmi MC; Malinverni S; Mangione PP; Palmer MT; Lampis A; Concardi M; Verona G; Canetti D; Arbustini E; Bellotti V; Giorgetti S
J Biol Chem; 2024 Apr; 300(4):107174. PubMed ID: 38499153
[TBL] [Abstract][Full Text] [Related]
24. Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage.
Lin Y; Marin-Argany M; Dick CJ; Redhage KR; Blancas-Mejia LM; Bulur P; Butler GW; Deeds MC; Madden BJ; Williams A; Wall JS; Dietz A; Ramirez-Alvarado M
Cytotherapy; 2017 Dec; 19(12):1426-1437. PubMed ID: 29037943
[TBL] [Abstract][Full Text] [Related]
25. Therapies for cardiac light chain amyloidosis: An update.
Aimo A; Buda G; Fontana M; Barison A; Vergaro G; Emdin M; Merlini G
Int J Cardiol; 2018 Nov; 271():152-160. PubMed ID: 30223349
[TBL] [Abstract][Full Text] [Related]
26. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.
Ami D; Lavatelli F; Rognoni P; Palladini G; Raimondi S; Giorgetti S; Monti L; Doglia SM; Natalello A; Merlini G
Sci Rep; 2016 Jul; 6():29096. PubMed ID: 27373200
[TBL] [Abstract][Full Text] [Related]
27. Systemic Amyloidosis Caused by Monoclonal Immunoglobulins: Soft Tissue and Vascular Involvement.
Hoffman JE; Dempsey NG; Sanchorawala V
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1099-1113. PubMed ID: 33099427
[TBL] [Abstract][Full Text] [Related]
28. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
[TBL] [Abstract][Full Text] [Related]
29. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.
Clos AL; Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Jackson GR; Kelly B; Beachkofsky TM; Kayed R
Br J Dermatol; 2011 Dec; 165(6):1349-54. PubMed ID: 21729025
[TBL] [Abstract][Full Text] [Related]
30. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.
Karimi-Farsijani S; Pfeiffer PB; Banerjee S; Baur J; Kuhn L; Kupfer N; Hegenbart U; Schönland SO; Wiese S; Haupt C; Schmidt M; Fändrich M
Nat Commun; 2024 Jun; 15(1):5121. PubMed ID: 38879609
[TBL] [Abstract][Full Text] [Related]
31. [AL Amyloidosis].
Ueda M
Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
[TBL] [Abstract][Full Text] [Related]
32. Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement.
Saith SE; Maurer MS; Patel AR
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1055-1068. PubMed ID: 33099423
[TBL] [Abstract][Full Text] [Related]
33. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Weiss BM; Wong SW; Comenzo RL
Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous light chain amyloidosis with multiple myeloma: A concise review.
Andrei M; Wang JC
Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):71-81. PubMed ID: 30261180
[TBL] [Abstract][Full Text] [Related]
35. Splenic plasma cells can serve as a source of amyloidogenic light chains.
Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
[TBL] [Abstract][Full Text] [Related]
36. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
[TBL] [Abstract][Full Text] [Related]
37. [AL amyloidosis].
Jaccard A; Desport E; Mohty D; Bridoux F
Rev Med Interne; 2015 Feb; 36(2):89-97. PubMed ID: 25194219
[TBL] [Abstract][Full Text] [Related]
38. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
[TBL] [Abstract][Full Text] [Related]
39. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
40. Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Lavatelli F; Nuvolone M; Ferraro G; Palladini G; Merlini G
Amyloid; 2017 Mar; 24(sup1):64-65. PubMed ID: 28434343
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
